Twist Bioscience CEO exercises options, sells shares
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported an option exercise and share sale on August 12, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported an option exercise and share sale on August 12, 2026. She exercised 19,952 Employee Stock Options at an exercise price of $26.66 per share, receiving an equal number of common shares. The same day, she sold 19,952 common shares at a weighted average price of $125.0756 per share in transactions executed under a previously adopted Rule 10b5-1 trading plan.
The option exercised relates to a grant expiring on November 18, 2028. Additional stock option holdings are reported with exercise prices of $5.95, $8.82, $23.33, and $67.85, with expirations between 2025 and 2030, showing remaining equity-based incentives.
Insider Trade Summary 10b5-1
Exercise and Sale: 19,952 shares ($1.96M approx. pre-tax spread)
Exercise and Sale
7 txns
Insider
Leproust Emily M.
Role
Chief Executive Officer
Sold
19,952 shs ($2.50M)
Approx. gross sale proceeds
$2.50M
Approx. exercise cost
$532K
Approx. pre-tax spread
$1.96M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) F7 | 19,952 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 19,952 | $26.66 | $532K |
| Sale | Common Stock F1, F2 | 19,952 | $125.0756 | $2.50M |
| holding | Employee Stock Option (right to buy) F3 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F4 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F5 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F6 | -- | -- | -- |
Holdings After Transaction:
Employee Stock Option (right to buy) — 133,269 contracts for 0 underlying shares (Direct);
Common Stock — 818,938 shares (Direct)
Footnotes (7)
- F1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025.
- F2. Represents the weighted average sales price per share. The shares sold at prices ranging from $125.00 to $125.25 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F3. The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
- F4. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
- F5. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
- F6. The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
- F7. 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
Key Figures
Options Exercised: 19,952 shares
Option Exercise Price: $26.66 per share
Shares Sold: 19,952 shares
+3 more
6 metrics
Options Exercised
19,952 shares
Employee Stock Options exercised into common stock on August 12, 2026
Option Exercise Price
$26.66 per share
Exercise price for 19,952 Employee Stock Options
Shares Sold
19,952 shares
Common shares sold on August 12, 2026
Weighted Average Sale Price
$125.0756 per share
Sale price, with trades between $125.00 and $125.25
10b5-1 Plan Adoption Date
May 27, 2025
Date the Rule 10b5-1 trading plan governing these trades was adopted
Option Expiration
November 18, 2028
Expiration date of the exercised Employee Stock Option grant
Key Terms
Rule 10b5-1 trading plan, Employee Stock Option (right to buy), weighted average sales price, performance stock options
4 terms
Rule 10b5-1 trading plan regulatory
"transactions were effected pursuant to a Rule 10b5-1 trading plan previously adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Employee Stock Option (right to buy) financial
"security_title: Employee Stock Option (right to buy)"
weighted average sales price financial
"Represents the weighted average sales price per share. The shares sold at prices"
performance stock options financial
"Represents performance stock options granted to the reporting person on September 1, 2020"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did TWST CEO Emily Leproust report on this Form 4?
Emily Leproust reported exercising 19,952 stock options at $26.66 per share and selling 19,952 common shares at a weighted average of $125.0756 per share on August 12, 2026, under a Rule 10b5-1 trading plan.
What options did the TWST CEO exercise in this Form 4 transaction?
Emily Leproust exercised 19,952 Employee Stock Options with an exercise price of $26.66 per share, converting them into an equal number of common shares. The option has an expiration date of November 18, 2028 and vesting terms described in a footnote.
Were the TWST CEO’s trades made under a Rule 10b5-1 plan?
Yes. A footnote states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2025. Such plans pre-schedule trades, which can reduce the informational value of transaction timing for investors.
What other stock options does the TWST CEO hold according to this filing?
Reported option holdings include Employee Stock Options with exercise prices of $5.95, $8.82, $23.33, and $67.85 per share, expiring between September 28, 2025 and August 31, 2030, each tied to Twist Bioscience common stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates